Table 1.
Clinical characteristics and genomic alterations in MECa.
| Muco-Epidermoid Carcinoma | |
| Number of cases | 118 |
| Median age (range) | 64 (16–89+) |
| Gender (M/F) | 58%/42% |
| GA per tumor | 4.88 |
| Cell Cycle Regulatory GA | |
| TP53 | 40.70% |
| CDKN2A | 52.50% |
| CDKN2B | 30.50% |
| CDK4 | 1.70% |
| CCND1 | 3.40% |
| RB1 | 3.40% |
| Chromosomal and Chromatin Related GA | |
| TERT | 15.00% |
| ARID1A | 2.50% |
| xRAS-RAF Pathway GA | |
| KRAS All | 5.10% |
| KRAS G12C | 2.50% |
| HRAS | 14.40% |
| BRAF | 1.70% |
| MTOR Pathway GA | |
| PTEN | 7.60% |
| PIK3CA | 16.90% |
| NF1 | 4.20% |
| TSC2 | 1.00% |
| DNA Damage Response Associated GA | |
| BRCA1 | 1.70% |
| BRCA2 | 5.90% |
| ATM | 4.20% |
| PALB2 | 0.80% |
| BAP1 | 18.60% |
| Receptor Tyrosine Kinase Targetable GA | |
| ERBB2 (amp/SV) | 5.9%/0% |
| EGFR (amp/SV) | 0.8%/0% |
| FGFR1 | 5.10% |
| FGFR2 | 0% |
| RET | 0% |
| ETV6lNTRK3 fusion | 0% |
| MET | 0% |
| KIT | 0.80% |
| Transcription Factor Genomic Alterations | |
| NFIB-MYB Fusion | 0% |
| ESR1 | 0% |
| AR | 0% |
| MYC | 1.70% |
| EWSR | 0% |
| Emerging Potentially Genomic Alterations | |
| NOTCH1 | 4.20% |
| NOTCH2 | 7.60% |
| MTAP | 13.70% |
| (F1CDx only) | (51 cases) |
| Immuno-Oncology Drug Biomarkers | |
| MSI high frequency | 0% |
| (100 cases) | |
| CD274 (PD-L1) amp | 0% |
| STK11 inactivating GA | 3.40% |
| MDM2 amp | 3.40% |
| Median TMB | 2.6 |
| TMB > 10% | 16.90% |
| TMB > 20% | 12.70% |
| PD-L1 low expression (≤49%) | 38.40% |
| (26 cases) | |
| PD-L1 high expression (>50%) | 4.20% |